Product Datasheet

GSDMDC1 Antibody - BSA Free NBP2-33422

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 1 Publications: 97

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-33422

Updated 4/13/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-33422



NBP2-33422


GSDMDC1 Antibody - BSA Free

GSDMDC1 Antibody - BSA Free	
Product Information	
Unit Size	0.1 ml
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS (pH 7.2), 40% Glycerol
Product Description	
Host	Rabbit
Gene ID	79792
Gene Symbol	GSDMD
Species	Human, Mouse, Rat, Porcine
Reactivity Notes	Use in Porcine reported in scientific literature (PMID:34890644) Mouse reactivity reported in scientific literature (PMID: 30473634). Rat reactivity reported in scientific literature (PMID: 32245616).
Immunogen	This antibody was developed against a recombinant protein corresponding to amino acids: GDNVYVVTEVLQTQKEVEVTRTHKREGSGRFSLPGATCLQGEGQGHLSQKKT VTIPSGSTLAFRVAQLVIDSDLDVLLFPDKKQRTFQPPATGHKRSTS
Product Application Details	
Applications	Western Blot, Simple Western, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Immunoprecipitation, Knockdown Validated, Knockout Validated
Recommended Dilutions	Western Blot 0.04 - 0.4 ug/mL, Simple Western 1:25, Immunocytochemistry/ Immunofluorescence Reactivity reported in scientific literature (PMID: 30250284)., Immunoprecipitation Reported in scientific literature (PMID: 33053349)., Immunohistochemistry-Paraffin Reported in scientific literature (PMID:34494385)., Knockout Validated Reactivity reported in scientific literature (PMID: 32796818)., Knockdown Validated Reactivity reported in scientific literature (PMID: 31216481)




Images


Analysis in human cell lines U2OS and HEK293 using anti-GSDMD antibody. Corresponding GSDMD RNA-seq data are presented for the same cell lines. Loading control: anti-HSP90B1.




GSDMD from cell lysates of THP1 treated by staphylococcus aureus alpha toxin was detected by immunoblot using GSDMD antibody (NBP2-33422) at 2 ug/mL. WB image submitted by a verified customer review.



SFV4-induced cell death in HOS and A549 cells. Lysates were harvested from SFV4-infected HOS and A549 cells (MOI = 10) at 6, 24 and 48 h. Full-length GSDMDFL, truncated and active GSDMDN-term (lower band, indicated by arrow) and mature IL-1betamat were detected by Western blot. Vinculin was used as internal loading control. Autophagy: HOS and A549 cells expressing eGFP-LC3 cells were infected with SFV4 (MOI = 10) and monitored by fluorescence microscopy. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/s41419-020-2236-3), licensed under a CC-BY license.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - miR-513c-5p negatively regulates caspase-1 expression in HUVECs. (A) The expression of miR-513c-5p after NC, miR-513c-5p mimics, INC & miR-513c-5p inhibitor transfection was evaluated by qRT-PCR. (B) The expression level of caspase-1 mRNA after NC, miR-513c-5p mimics, INC & miR-513c-5p inhibitor transfection was detected by qRT-PCR. (C,D) Expression of caspase-1 in HUVECs were detected after transfection NC, miR-513c-5p mimics, INC, miR-513c-5p inhibitor by immunofluorescence staining (magnification, ×40). Scale bar = 200 μ m. (E,F) Protein expression levels of caspase-1 & GSDMD were examined by Western blot. (G) The expression of IL-1 β & IL-18 was detected by ELISA. *p < 0.05, **p < 0.01, & ***p < 0.001, ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35445025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




С

Western Blot: GSDMDC1 Antibody [NBP2-33422] - Pyroptosome formation in the cortex & hippocampus of aged mice: Aging induces laddering of ASC in cortex (a) & hippocampus (b) of mice, indicating formation of the pyroptosome, an oligomerization of ASC that leads to pyroptosis. Representative immunoblot & quantification of gasdermin-D in the cortex (c) & hippocampus (d) of aged mice when compared to young. Gasdermin-D is significantly elevated in the cortex & hippocampus of aged mice. Data presented as mean+/-SEM. N = 5 per group. * p < 0.05 Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30473634), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - Expressions of caspase-1, GSDMD, IL-1β, & IL-18 are up-regulated in DVT patients. (A) mRNA level of caspase-1 in the PBMCs from 30 DVT patients & 30 controls was determined by qRT-PCR. (B) Caspase-1 & GSDMD protein levels were measured in PBMCs of DVT subjects & controls by Western blot. (C,D) Protein levels of IL-1β & IL-18 in the serum from 12 DVT patients & 12 controls were determined by ELISA. ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35445025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - Overexpression of miR-513c-5p suppresses pyroptosis of VECs & DVT formation by inhibiting caspase-1. (A) Expression of miR-513c-5p in vascular tissue was detected by qRT-PCR in DVT mice treated with NC, miR-513c-5p mimics, respectively. (B) Relative expression of miR-513c-5p was measured by qRT-PCR in PBMCs of DVT each treatment group. (C) Confocal microscopy images of miR-513c-5p expression in vascular tissues (miR-513c-5p, red; DAPI, blue) (magnification, ×200). Scale bars = 100 μm. (D) H&E staining of serial cross sections of inferior vena cava Cleaved Caspase-1 (IVC) from DVT mice treated with NC, miR-513c-5p mimics at 48 h (magnification, $\times 40$), respectively. Scale bars = 500 μ m. (E) Representative images of thrombi in each treatment group were detected by vascular ultrasound at 48 h post-operation. (F) Thrombus length & weight at 48 h post-operation in DVT mice (n = 15) treated with NC, miR-513c-5p mimics. (G) Caspase-1 mRNA level was determined by qRT-PCR in vascular tissue of each treatment group. (H) Caspase-1 & GSDMD protein levels were determined by Western blot in vascular tissue of DVT each treatment group. (I) IL-1β & IL-18 protein levels in vascular tissue were determined by ELISA in DVT each treatment group. **p < 0.01, ***p < 0.001, & ****p < 0.0001. Image collected & cropped by CiteAb from the following publication

Caspase-1 DVT-rhit DVT-rhitrites

Cleaved Caspase-1 20KD

GSDMD 55KD


Cleaved GSDMD 30KD

GAPDH 36KD


(https://pubmed.ncbi.nlm.nih.gov/35445025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GSDMDC1 Antibody [NBP2-33422] - Caspase-1 inhibitor (vx-765) inhibits the formation of DVT in vivo. (A,B) H&E staining of serial cross sections of IVC from Ctrl, Sham, DVT, DVT+vehicle, DVT+vx-765, DVT+vehicle+miR-513c-5p inhibitor, DVT+vx-765+miR-513c-5p inhibitor at 48 h (magnification, ×40). Scale bars = 500 µm. (C,D) Thrombus length & weight at 48 h post-operation in the different treatment groups after the administration of caspase-1 inhibitor (vx-765) (n = 15 in each group). (E) Representative images of thrombi in each treatment group were detected by vascular ultrasound at 48 h post-operation. (F) Caspase-1 & GSDMD protein levels were determined by Western blot in vascular tissue of DVT animal group & vx-765-treated groups. (G) Expression of IL-1β & IL-18 in vascular tissue were detected by ELISA with vx-765 treated each group. **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35445025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: GSDMDC1 Antibody [NBP2-33422] - mIL-18 release from P unprimed monocytes is dependent on GSDMD. (A, B) Unprimed THP-1 cells pre-incubated with punical agin (50 µM, 15 min) prior to treatment with nigericin (10 μM, 45 min). (C, D) Unprimed WT & GSDMD KO THP-1s were treated with nigericin (10 µM, 45 min). (A, C) Secreted IL-18 was measured by ELISA & cell death was measured by LDH assay & shown as percentage relative to total cell death, n=3 independent biological replicates, mean ± S.D., *P < 0.05; ***P < 0.001; ****P < 0.0001; ns (not significant) using one-way ANOVA comparing each sample to nigericin only treated sample (A) or two-way ANOVA comparing UT to nigericin treated WT THP-1s as well as nigericin treated WT THP-1s to nigericin treated GSDMD KO THP-1s. (C). (B, D) Western blot analysis of THP-1 cells for mIL-18 (18 kDa), pro-IL-18 (24 kDa), mCaspase-1 (20 kDa), pro-Caspase-1 (45 kDa), GSDMD full length (FL, 53 kDa), GSDMD Nterminus (NT, 31 kDa), as well as loading control β-actin (42 kDa). Blots are representative of at least 3 independent experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33101286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: GSDMDC1 Antibody [NBP2-33422] - Priming is not required for NLRP3 inflammasome activation in human monocytes in vitro. (A, B) Undifferentiated THP-1 cells (n=6 independent biological replicates) & (C, D) primary CD14+ monocytes (n=6 independent biological replicates (each point represents a different blood donor)) were left untreated or primed with LPS (1 µg/ml, 4 h) prior to treatment with nigericin (10 μM, 45 min) to activate the NLRP3 inflammasome. (A, C) IL-1\(\beta \) & IL-18 were measured by ELISA & cell death was measured by LDH assay & shown as percentage relative to total cell death, mean ± S.D., *P < 0.05; **P < 0.01; ***P < 0.001; ns (non significant) using oneway ANOVA comparing all groups. (B, D) Western blot analysis for mlL-18 (18 kDa), pro-IL-18 (24 kDa), mIL-1β (17 kDa), pro-IL-1β (34 kDa), mCaspase-1 (20 kDa), pro-Caspase-1 (45 kDa), GSDMD full length (FL, 53 kDa), GSDMD N-terminus (NT, 31 kDa), UBE2L3 (17.9 kDa), NLRP3 (113 kDa), as well as loading control β-actin (42 kDa). Blots are representative of at least 3 independent biological experiments & in case of monocytes 3 different blood donors. Image collected & cropped by CiteAb from the following publication



(https://pubmed.ncbi.nlm.nih.gov/33101286), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - Glyburide attenuates C NLRP3 inflammasome-mediated pyroptosis in HCECs infected with HKCA. HCECs were pretreated with potassium (K+) channel inhibitor (glyburide) for 2 h, & then were incubated with HKCA (MOI = 20) for 24 h. (A,B) Western blot showing the protein levels of NLRP3 in HCECs treated with various concentrations of glyburide (50, 100 & 200 μ M) (n = 3). (C,D) Glyburide treatment (200 μM) suppressed the levels of pyroptosis-related proteins (ASC, cleaved CASP1, N-GSDMD, cleaved IL-1β & cleaved IL-18) in HCECs challenged with HKCA at 20:1 for 24 h (n = 3). (E) Immunofluorescence analysis of NLRP3, CASP1 & ASC in HCECs pretreated with or without glyburide (200 μ M) for 24 h (n = 3). Scale bar = 20 µm; magnification 400×. (F) LDH release of HCECs treated with glyburide (200 µM) (n = 6). CASP1: caspase-1; Clv-CASP1: cleaved CASP1; Clv-IL-1β: cleaved IL-1β; Clv-IL-18: cleaved IL-18; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. N.S. P>0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: GSDMDC1 Antibody [NBP2-33422] - Pyroptosis is occurred in mouse corneas of C. albicans keratitis. (A) RT-qPCR analysis of the mRNA levels of pyroptosis-associated genes (ASC/CASP1/GSDMD/IL-1β/IL-18) in mouse corneas at 0 (control), 1, 3, & 7 dpi (n = 3). (B,C) Western blot detecting pyroptosis-related proteins of ASC, cleaved CASP1, cleaved IL-1β, cleaved IL-18, F-GSDMD & N-GSDMD in mouse corneas at 0 (control), 1, 3, & 7 dpi (n = 3). (D) Double-immunofluorescence staining of CASP1 & TUNEL in C. albicans infected-corneas compared with mock-infected controls (n = 3; Scale bar = 20 μm; magnification 400×). CASP1: caspase-1; Clv-CASP1:cleaved CASP1; Clv-IL-1β:cleaved IL-1β; Clv-IL-18:cleaved IL-18; F-GSDMD: p53 form of GSDMD: N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean \pm SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY


license. Not internally tested by Novus Biologicals.

В


Western Blot: GSDMDC1 Antibody [NBP2-33422] - NLRP3 knockdown attenuates the pyroptosis in mouse C. albicans keratitis. (A-C) RT-qPCR analysis & western blot showing the mRNA & protein levels of pyroptosis-related molecules in C. albicans-infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3- shRNA compared with mock controls (n = 3). (D) Immunofluorescence staining of ASC, CASP1 & GSDMD in C. albicans-infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3- shRNA compared with mock controls (n = 3). (E) Doubleimmunofluorescence staining of CASP1 & TUNEL in the mice cornea of Ad-NLRP3-shRNA group compared with the Ad-GFP-shRNA group (n = 3). Scale bar = 20 µm; magnification 400×. FK: fungal keratitis. CASP1: caspase-1; Clv-CASP1:cleaved CASP1; Clv-IL-1B:cleaved IL-1B: Clv-IL-18:cleaved IL-18; F-GSDMD: p53 form of GSDMD; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - Knockdown of miR-513c-5p promotes pyroptosis of VECs & DVT formation by increasing caspase-1. (A) The expression level of miR-513c-5p in vascular tissue was detected by gRT-PCR in DVT mice treated with INC, miR-513c-5p inhibitor, respectively. (B) Expression of miR-513c-5p in PBMCs was detected by gRT-PCR in DVT mice treated with INC, miR-513c-5p inhibitor, respectively. (C) Confocal microscopy images of miR-513c-5p expression in vascular tissues (miR-513c-5p, red; DAPI, blue) (magnification, ×200). Scale bars = 100 µm. (D) H&E staining of serial cross sections of inferior vena cava (IVC) from DVT mice treated with INC, miR-513c-5p inhibitor at 48 h (magnification, ×40). Scale bars = 500 µm. (E) Representative images of thrombi in each treatment group were detected by vascular ultrasound at 48 h post-operation. (F) Thrombus length & weight at 48 h post-operation in the different treatment groups (n = 15 in each group). (G) Caspase-1 mRNA level was determined by qRT-PCR in vascular tissue of each treatment group. (H) Caspase-1 & GSDMD protein levels were determined by Western blot in vascular tissue of DVT mice treated with INC, miR-513c-5p inhibitor. (I) IL-1β & IL-18 protein levels in vascular tissue were determined by ELISA in INC, miR-513c-5p inhibitor treated DVT mice models, respectively. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35445025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: GSDMDC1 Antibody [NBP2-33422] - Pyroptosis & IL-1ß release is dependent on the B. pseudomallei T3SS-3.hMDMs were infected with B. pseudomallei (MOI 300) for 3h. (A & B) Cell death induction & intracellular bacterial burden were determined at 0 & 3h p.i. Shown are the median & interquartile range of at least three independent experiments with different donors performed in technical duplicates. (C) IL-1β secretion was determined 3h p.i. Data are presented as median & interquartile range of four independent experiments with different donors performed in duplicates. (D) Caspase-1 & gasdermin-D processing were investigated 3h p.i. Lysates were re-probed for β-actin. For immunoblot analysis one representative experiment of at least three with different donors is shown. (E) Growth analysis of wt & ΔbsaL was performed. Shown are mean values of three independent experiments performed in technical triplicates. (*p < 0.05, **p < 0.01). n.i. (not infected), wt (wild type), b.d. (below detection), hours (h), p.i. (post infection), GSDMD (gasdermin D). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33137811), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: GSDMDC1 Antibody [NBP2-33422] - Priming is not required for NLRP3 inflammasome activation in human monocytes in vitro. (A, B) Undifferentiated THP-1 cells (n=6 independent biological replicates) & (C, D) primary CD14+ monocytes (n=6 independent biological replicates (each point represents a different blood donor)) were left untreated or primed with LPS (1 μg/ml, 4 h) prior to treatment with nigericin (10 μM, 45 min) to activate the NLRP3 inflammasome. (A, C) IL-1β & IL-18 were measured by ELISA & cell death was measured by LDH assay & shown as percentage relative to total cell death, mean ± S.D., $^*P < 0.05$; $^{**}P < 0.01$; $^{***}P < 0.001$; ns (non significant) using oneway ANOVA comparing all groups. (B, D) Western blot analysis for mlL-18 (18 kDa), pro-IL-18 (24 kDa), mIL-1β (17 kDa), pro-IL-1β (34 kDa), mCaspase-1 (20 kDa), pro-Caspase-1 (45 kDa), GSDMD full length (FL, 53 kDa), GSDMD N-terminus (NT, 31 kDa), UBE2L3 (17.9 kDa), NLRP3 (113 kDa), as well as loading control β-actin (42 kDa). Blots are representative of at least 3 independent biological experiments & in case of monocytes 3 different blood donors. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33101286), licensed under a CC-BY

license. Not internally tested by Novus Biologicals.

Western Blot: GSDMDC1 Antibody [NBP2-33422] - Heat-killed C. albicans (HKCA) activates NLRP3 inflammasome & induces pyroptosis in human corneal epithelial cells (HCECs). (A) The mRNA expression of NLRP3 in HCECs challenged with HKCA at an MOI of 1:500, 1:50, 1:5, 2:1, or 20:1 respectively for 4 hours was evaluated by RT-qPCR (n = 5). (B-D) The mRNA & protein expression of NLRP3 in HCECs exposed to HKCA (MOI = 20) for 0 (control), 2, 4, 8, 12, or 24 h (n = 3). (E) NLRP3 fluorescence intensity was evaluated using immunofluorescent staining for different times (12–36 h). (n = 3; Scale bar = 20 µm; magnification 400×). (F) Lactate dehydrogenase (LDH) of HCECs treated with HKCA (MOI = 20) for 24 h (n = 6). (G) The mRNA levels of ASC, CASP1, IL-1 β , IL-18 & GSDMD in HCECs exposed to HKCA (MOI = 20) for different times (n = 3). (H,I) The protein expression of pyroptosis-related proteins (ASC, cleaved CASP1, N-GSDMD, cleaved IL-1β & cleaved IL-18) was examined by western blot (n = 3). CASP1: caspase-1; Clv-CASP1: cleaved CASP1; Clv-IL-1\(\beta\): cleaved IL-1\(\beta\); Clv-IL-18: cleaved IL-18; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001 vs. control group. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Wu A, Zhong C, Song X, Yuan W et Al. The activation of LBH-CRYAB signaling promotes cardiac protection against I/R injury by inhibiting apoptosis and ferroptosis iScience 2024-04-25 [PMID: 38660406]

Tsamouri LP, Hsiao JC, Wang Q, Geeson MB et Al. The hydrophobicity of the CARD8 N-terminus tunes inflammasome activation Cell Chem Biol 2024-07-11 [PMID: 38991619]

Fontana P, Du G, Zhang Y, Zhang H et Al. Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity Cell 2024-09-07 [PMID: 39243763]

Yao J, Li Y, Liu X, Liang W et Al. FUBP3 mediates the amyloid-?-induced neuronal NLRP3 expression Neural Regen Res 2024-09-10 [PMID: 39254567]

Sun Y, Pu Z, Zhao H et Al. Vitamin D can mitigate sepsis-associated neurodegeneration by inhibiting exogenous histone-induced pyroptosis and ferroptosis: Implications for brain protection and cognitive preservation Brain Behav Immun 2024-11-19 [PMID: 39566666]

Cai H, Zhang J, Xu H et Al. ALOX5 drives the pyroptosis of CD4(+) T cells and tissue inflammation in rheumatoid arthritis Sci Signal 2024-02-29 [PMID: 38412254]

Vind AC, Wu Z, Firdaus MJ et Al. The ribotoxic stress response drives acute inflammation, cell death, and epidermal thickening in UV-irradiated skin in vivo Mol Cell 2024-11-25 [PMID: 39591967]

Zi G, Chen J, Peng Y et Al. Hyperthermia and cisplatin combination therapy promotes caspase-8 accumulation and activation to enhance apoptosis and pyroptosis in cancer cells Int J Hyperthermia 2024-04-19 [PMID: 38632954]

Yu Q, Yang Y, Xu T et Al. Palmitoleic acid protects microglia from palmitate-induced neurotoxicity in vitro PLoS One 2024-01-19 [PMID: 38241239]

Sun, Y;Lu, Y;Liu, L;Saaoud, F;Shao, Y;Xu, K;Drummer Iv, C;Cueto, R;Shan, H;Jiang, X;Zhao, H;Wang, H;Yang, X; Caspase-4/11 promotes hyperlipidemia and chronic kidney disease-accelerated vascular inflammation by enhancing trained immunity JCI insight 2024-07-18 [PMID: 39024553]

Wang Q, Shan L The CARD8 inflammasome drives CD4+T-cell depletion in HIV-1 infection bioRxiv 2023-03-20

Luke CJ, Markovina S, Good M et al. Lysoptosis is an evolutionarily conserved cell death pathway moderated by intracellular serpins Communications biology 2022-01-12 [PMID: 35022507]

More publications at http://www.novusbio.com/NBP2-33422





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA

Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449

Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP2-33422

NBP2-33422PEP GSDMDC1 Recombinant Protein Antigen

HAF008 Goat anti-Rabbit IgG Secondary Antibody [HRP]

NB7160 Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]

NBP2-24891 Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-33422

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

